REDHILL BIOPHAR/S (NASDAQ:RDHL) received a $36.00 price objective from equities research analysts at HC Wainwright in a note issued to investors on Wednesday, November 14th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 410.64% from the stock’s previous close.

The analysts wrote, “We have updated our model to reflect the reported 3Q18 financials. Currently, we project revenues of $10.4M and a net loss of $0.18 per share for 2018. The company also reported approximately $43M in cash and cash equivalents at the end of 3Q18, which we believe is sufficient to fund operations into 2Q19.””

Several other research firms have also recently commented on RDHL. ValuEngine cut shares of REDHILL BIOPHAR/S from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Zacks Investment Research lowered shares of REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.81.

NASDAQ RDHL traded up $0.02 during trading on Wednesday, reaching $7.05. The company’s stock had a trading volume of 491,989 shares, compared to its average volume of 138,266. The stock has a market capitalization of $149.55 million, a PE ratio of -2.71 and a beta of 0.88. REDHILL BIOPHAR/S has a 1-year low of $4.40 and a 1-year high of $11.49.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.40) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.40). REDHILL BIOPHAR/S had a negative net margin of 461.55% and a negative return on equity of 112.99%. The business had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $2.54 million. On average, analysts expect that REDHILL BIOPHAR/S will post -1.76 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Disciplined Growth Investors Inc. MN bought a new stake in shares of REDHILL BIOPHAR/S in the 3rd quarter worth about $295,000. Ibex Investors LLC grew its holdings in REDHILL BIOPHAR/S by 5.4% during the 3rd quarter. Ibex Investors LLC now owns 527,000 shares of the biotechnology company’s stock worth $4,653,000 after acquiring an additional 27,000 shares during the last quarter. Renaissance Technologies LLC bought a new stake in REDHILL BIOPHAR/S during the 3rd quarter worth about $1,226,000. JPMorgan Chase & Co. grew its holdings in REDHILL BIOPHAR/S by 61.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock worth $652,000 after acquiring an additional 28,102 shares during the last quarter. Finally, Clear Harbor Asset Management LLC bought a new stake in REDHILL BIOPHAR/S during the 3rd quarter worth about $323,000. 32.27% of the stock is currently owned by institutional investors and hedge funds.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.

See Also: How dollar cost averaging works

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.